Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine

Kuriyama, Kodai; Kitamura, Yoshihisa; Tsuji, Taisuke; Nishikawa, Rina; Hiroaki, Nagata; Ohshiro, Muneo; Sugitani, Mio; Hirakawa, Yoshiko; Matsumoto, Yosuke; Iwai, Toshiki; Uchiyama, Hitoji

doi:10.1016/j.currproblcancer.2021.100813

Cited by 8 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, obinutuzumab is thought to be more effective in B-cell depletion than previous agents (eg, rituximab) because of a different binding geometry. 8 , 9 Kuriyama et al 10 described a case of follicular lymphoma and PNP that was successfully treated with combined therapy of bendamustine and obinutuzumab.…”

Section: Discussionmentioning

confidence: 99%

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus

Freund¹,

Trautinger

Kopetzky

et al. 2022

JAAD Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus

Freund¹,

Trautinger

Kopetzky

et al. 2022

JAAD Case Reports

View full text Add to dashboard Cite

“…Can Chen and co-authors in the same publication describe a first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL. Also Kodai Kuriyama and co-authors described successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine (8). It can be a promising prognosis for future methods and algorithms of treatment.…”

Section: Paraneoplastic Pemphigus-clinical Features and Diagnosismentioning

confidence: 99%

Paraneoplastic pemphigus and reported, identified underlying diseases

Iwańczuk

2024

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Pemphigus is a rare group of autoimmune diseases that promote development of various skin eruptions, the most commonly it presents with blisters. The several types of pemphigus are: pemphigus vulgaris, pemphigus foliaceus, intraepidermal neutrophillic IgA dermatosis and especially rare type- paraneoplastic pemphigus, which is main topic of this publication. Paraneoplastic pemphigus is a disease which affects patients with developing carcinogenesis process. Usually it is a malignant process, but there are also some cases which describe paraneoplastic pemphigus associated with benign tumors. Because of its occurence our current level of knowledge about different aspects of paraneoplastic pemphigus is not final and as comprehensive as researchers and patients wish. Aim of study: The main purpose of this publication is presentation a review of literature about paraneoplastic pemphigus- its epidemiology, physiopathology, pathomorfology, clinical features, and description of different types of benign or malignant processes which concomitence with paraneoplastic pemphigus. State of knowledge: Paraneoplastic pemphigus is a rare autoimmune disease, which aspects are not widely described, but there are some reports about epidemiology, pathophysiology, histopathology, treatment and associated confirmed malignancies. The challenge for future is to formulate clear, formal, treatment protocols for paraneoplastic pemphigus. Conclusion: Paraneoplastic pemphigus is a very fascinating disease for researchers because there are still very limited reports and statistics about this very rare disorder. Nonetheless year by year our level of knowledge about pathogenesis, clinical features, associated malignant and benign processes is growing and it can affect more personalized, effective treatment methods and protocoles.

show abstract

“…However, a great variety of skin manifestations, ranging from flaccid bullae to widespread lichenoid eruptions, have been observed in PAMS patients. Clinically, as well as histologically, PAMS can also mimic erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), particularly when cutaneous lesions are characterized by interface dermatitis with necrotic keratinocytes [1][2][3][4][5][6][7]. Lymphoproliferative diseases represent the most frequently identified neoplasia associated with PAMS, accounting for over 80% of cases [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…Almost 60% of PNP cases are associated with non-Hodgkin lymphomas and chronic lymphocytic leukemia. In fact, there are 21 cases of patients who suffered from follicular lymphoma (FL) associated with PAMS [5][6][7]. Among a broad range of possible proteins targeted by autoantibodies, plakin proteins (envoplakin, epiplakin, and periplakin) are the most characteristic of PAMS.…”

Section: Introductionmentioning

confidence: 99%

“…Here, we describe a patient who was initially diagnosed with vaccine-induced chronically recurrent SJS, accompanied by a chronic excess of peripheral CD8+ lymphocytes. One and a half years later, following the detection of follicular lymphoma, the patient was finally diagnosed with antibody-negative PAMS, with a fatal outcome three weeks later [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes

et al. 2022

View full text Add to dashboard Cite

Paraneoplastic autoimmune multiorgan syndrome (PAMS) is a life-threatening autoimmune disease associated with malignancies. Here, we present a patient initially misdiagnosed with “chronic” Stevens–Johnson syndrome. Over a year later, the patient was diagnosed with stage IV follicular lymphoma and treated with an anti-CD20 antibody. At this time, his skin condition had significantly worsened, with erythroderma and massive mucosal involvement, including in the mouth, nose, eyes, and genital region. Histopathology revealed lichenoid infiltrates with interface dermatitis, dyskeratoses, necrotic keratinocytes, and a dense CD8+ infiltrate with strong epidermotropism. Direct and indirect immunofluorescence tests for autoantibodies were negative. Remarkably, we retrospectively discovered a chronic increase in peripheral CD8+ lymphocytes, persisting for over a year. Consequently, the patient was diagnosed with antibody-negative PAMS. Three weeks later, he succumbed to respiratory failure. This dramatic case highlights the challenges in diagnosing PAMS, particularly in cases where immunofluorescence assays are negative. Importantly, we observed, for the first time, a chronic excess of CD8+ peripheral blood lymphocytes, associated with PAMS, consistent with the systemic, autoreactive T-cell-driven processes that characterize this condition.

show abstract

Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine

Cited by 8 publications

References 24 publications

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus

Paraneoplastic pemphigus and reported, identified underlying diseases

Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes

Contact Info

Product

Resources

About